Access Statistics for Mary K. Olson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Pharmaceutical Expenditure and Regulatory Policy in the NHS 0 0 0 0 1 1 1 333
Total Working Papers 0 0 0 0 1 1 1 333


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Agency Rulemaking, Political Influences, Regulation, and Industry Compliance 0 0 0 0 2 2 8 368
Are novel drugs more risky for patients than less novel drugs? 0 0 0 29 2 3 15 128
Eliminating the U.S. drug lag: Implications for drug safety 0 0 0 13 0 1 11 119
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 1 3 3 3 13 33
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 0 7 2 2 10 66
Firm Characteristics and the Speed of FDA Approval 0 0 1 42 0 2 7 149
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? 0 0 0 3 2 2 8 37
Pharmaceutical Policy Change and the Safety of New Drugs 0 0 2 9 1 1 9 76
Political Influence and Regulatory Policy: The 1984 Drug Legislation 0 0 0 0 0 2 7 183
Reassessing the impact of health IT: Hidden costs and consequences of vendor heterogeneity 0 0 2 2 4 5 22 22
Regulatory Agency Discretion among Competing Industries: Inside the FDA 0 0 0 0 1 1 8 195
Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA 0 0 0 25 2 3 16 136
Substitution in Regulatory Agencies: FDA Enforcement Alternatives 0 0 0 0 1 1 4 204
The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D 0 0 0 12 3 3 6 76
The risk we bear: The effects of review speed and industry user fees on new drug safety 0 0 2 28 2 2 8 145
Total Journal Articles 0 0 8 173 25 33 152 1,937


Statistics updated 2026-05-06